WO2000063263A1 - Biodegradable poly(propylene fumarate) networks cross linked with poly(propylene fumarate)-diacrylate macromers - Google Patents
Biodegradable poly(propylene fumarate) networks cross linked with poly(propylene fumarate)-diacrylate macromers Download PDFInfo
- Publication number
- WO2000063263A1 WO2000063263A1 PCT/US2000/010049 US0010049W WO0063263A1 WO 2000063263 A1 WO2000063263 A1 WO 2000063263A1 US 0010049 W US0010049 W US 0010049W WO 0063263 A1 WO0063263 A1 WO 0063263A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ppf
- poly
- propylene fumarate
- fumarate
- diacrylate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/06—Unsaturated polyesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
- C08G63/668—Polyesters containing oxygen in the form of ether groups derived from polycarboxylic acids and polyhydroxy compounds
- C08G63/676—Polyesters containing oxygen in the form of ether groups derived from polycarboxylic acids and polyhydroxy compounds in which at least one of the two components contains aliphatic unsaturation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/91—Polymers modified by chemical after-treatment
- C08G63/914—Polymers modified by chemical after-treatment derived from polycarboxylic acids and polyhydroxy compounds
- C08G63/918—Polycarboxylic acids and polyhydroxy compounds in which at least one of the two components contains aliphatic unsaturation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
- C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
- C08G81/024—Block or graft polymers containing sequences of polymers of C08C or C08F and of polymers of C08G
- C08G81/025—Block or graft polymers containing sequences of polymers of C08C or C08F and of polymers of C08G containing polyether sequences
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
- C08L67/06—Unsaturated polyesters
- C08L67/07—Unsaturated polyesters having terminal carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
Definitions
- n-vinyl pyrrolidone ( ⁇ VP) as a crosslinking reagent.
- the crosslinking agent bonds at its ends to separate, larger propylene fumarate molecules, serving as a link or bridge between them. While these compounds exhibit promising characteristics, it is believed preferable to avoid the presence of any unreacted ⁇ VP after in situ polymerization.
- the poly(vinyl pyrrolidone) (PVP) links in the crosslinked PPF networks are non-degradable.
- network refers to polymeric molecules that have been cross linked so as to effectively form a continuous molecule.
- gel is sometimes used to refer to the same type of cross linked systems.
- Figure 1 is a schematic chemical diagram illustrating the synthesis of poly(propylene fumarate);
- FIG. 4 shows a believed mechanism for the synthesis reactions of PPF-diacrylate, using PPF as a starting point.
- PPF was synthesized by the preferred two-step reaction process described previously. Specifically, fumaryl chloride was added dropwise to a solution of propylene glycol in methylene chloride at 0°C under nitrogen in the presence of K 2 CO 3 . After addition of fumaryl chloride, the reaction mixture was stirred for an additional 2 h at 0°C and then water was added to dissolve the inorganic salt. The organic layer was separated and dried with Na 2 SO . After filtration and evaporation of the solvent, the formed di-(2-hydroxylpropyl) fumarate underwent transesterification reaction to produce PPF at a temperature of 160°C and a pressure of 0.5 mm Hg. PPF was purified through solution precipitation in chloroform and petroleum ether.
- Di-(2-hydroxylpropyl) fumarate was obtained from the reaction of fumaryl chloride with propylene glycol as described above.
- acryloyl chloride 26 g, 0.3 mol
- the reaction mixture was stirred overnight at room temperature. The white precipitate was filtered off and the CH C1 2 solvent was rotary evaporated.
- PPF/PPF-DA polymer networks 1 g PPF was mixed with 1.13 g PPF-DA (the double bond ratio of PPF/PPF-DA is 1) at room temperature. 6.5 mg BP were dissolved in 0.1 mL of CH 2 C1 2 and the solution was added to the PPF/PPF-DA mixture. After thorough mixing on Vortexer, 4 ⁇ L DMT were added with rapid stirring, then, the mixture was molded as a cylinder or a film. For mechanical testing, the mixture was placed into cylindrical vials of 6 mm diameter suspended in a 37 °C water bath. After 2 h, the cylinders were removed from the vials and cut into 12 mm long segments using a diamond saw. For degradation studies, PPF/PPF-DA network films were obtained by polymerization of the PPF/PPF-DA mixture in a Teflon mold with 1 mm depth. Mechanical Testing
- the molecular weights of PPF and degradation copolymer were determined relative to polystyrene standards in chloroform by gel permeation chromatography with a conventional differential refractometer detector.
- a Styragel HR2 column 300 x 7.8 mm, 5 nm, mixed bed, Waters, Milford, MA
- a Phenogel guard column 50 x 7.8 mm, 5 nm, mixed bed, Phenomenex
- acetone was chosen as a solvent to extract the monomeric products, because the possible degradation products, fumaric acid and propylene glycol, have relatively high solubility in acetone while poly(acrylic acid-co- fumaric acid) is barely soluble in it.
- Analytical gas chromatography (GC) was carried out on a HP 5890A instrument equipped with a AT1701 capillary column (0.25 mm x 30 m) and FID detectors. Analytical GC conditions were 80°C for 5 min, ramp at 10°C/min to 250°C, hold 10 min.
- Propylene glycol acetonide came from the reaction of propylene glycol and acetone under acid catalysis. During the work-up of the degradation reaction, strong acid, HC1, was used to convert the degraded sodium salts to the corresponding acids in order to render them soluble in organic solvents. When acetone was used as the extracting solvent, the propylene glycol was converted completely to its acetonide under the acidic conditions.
- the acetone-insoluble degradation product poly(acrylic acid-co-fumaric acid), did not dissolve in other organic solvents including CHC1 3 .
- CHC1 3 organic solvents including CHC1 3 .
- the esterified copolymer was soluble in CHC1 3 for GPC measurement.
- the GPC result showed that this material had a number average molecular weight of 2,340 and a weight average molecular weight of 5,080. These molecular weights are well below the threshold value of 70,000 for hydrophilic polymers that are passively excreted by the kidneys.
- PPF-DA ( Figure 3), which showed no OH stretching band in the region of 3500-3100 cm-1.
- the integration ratio of acrylate to fumarate vinyl protons allows determination of the molecular weight of PPF-DA.
- the 1H NMR spectrum gives the ratio of 1 : 1, which implies presence of 3 fumarate units in this PPF-DA.
- New biodegradable poly(propylene fumarate)-based polymer networks can be synthesized by radical reaction of PPF and newly synthesized PPF-DA. These networks can alternatively be referred to as "gels.”
- the present PPF/PPF-DA polymer networks possess strong mechanical properties.
- the compressive strength and modulus of the PPF/PPF-DA polymer networks tested spanned a wide range and were mainly affected by the PPF/PPF-DA double bond ratio and the molecular weight of PPF-DA. All crosslinked networks showed very low water absorption.
- These polymer networks degrade by hydrolysis of the ester linkage to biocompatible, water-soluble products that include propylene glycol, fumaric acid, and poly (acrylic acid-co-fumaric acid).
- the good mechanical properties and degradation to biocompatible products make these new PPF/PPF-DA polymer networks well-suited for use as biomaterial scaffolds in orthopaedic tissue engineering.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU43496/00A AU775913B2 (en) | 1999-04-16 | 2000-04-14 | Biodegradable poly(propylene fumarate) networks cross linked with poly(propylenefumarate)-diacrylate macromers |
EP00923355A EP1210379B1 (en) | 1999-04-16 | 2000-04-14 | Biodegradable poly(propylene fumarate) networks cross linked with poly(propylene fumarate)-diacrylate macromers |
JP2000612348A JP2002542349A (en) | 1999-04-16 | 2000-04-14 | Biodegradable poly (propylene fumarate) network cross-linked with poly (propylene fumarate) -diacrylate macromer |
DE60034045T DE60034045T2 (en) | 1999-04-16 | 2000-04-14 | Biodegradable polypropylene fumarate networks crosslinked with polypropylene fumarate diacrylate macromers |
CA002370330A CA2370330C (en) | 1999-04-16 | 2000-04-14 | Biodegradable poly(propylene fumarate) networks cross linked with poly(propylene fumarate)-diacrylate macromers |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12957799P | 1999-04-16 | 1999-04-16 | |
US60/129,577 | 1999-04-16 | ||
US14699199P | 1999-08-03 | 1999-08-03 | |
US60/146,991 | 1999-08-03 | ||
US16738899P | 1999-11-24 | 1999-11-24 | |
US16732899P | 1999-11-24 | 1999-11-24 | |
US60/167,328 | 1999-11-24 | ||
US60/167,388 | 1999-11-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000063263A1 true WO2000063263A1 (en) | 2000-10-26 |
Family
ID=27494811
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/010139 WO2000062630A1 (en) | 1999-04-16 | 2000-04-14 | Functionalized poly(propylene fumarate) and poly(propylene fumarate-co-ethylene glycol) |
PCT/US2000/010051 WO2000063268A1 (en) | 1999-04-16 | 2000-04-14 | Poly(propylene fumarate) cross linked with poly(ethylene glycol) |
PCT/US2000/010049 WO2000063263A1 (en) | 1999-04-16 | 2000-04-14 | Biodegradable poly(propylene fumarate) networks cross linked with poly(propylene fumarate)-diacrylate macromers |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/010139 WO2000062630A1 (en) | 1999-04-16 | 2000-04-14 | Functionalized poly(propylene fumarate) and poly(propylene fumarate-co-ethylene glycol) |
PCT/US2000/010051 WO2000063268A1 (en) | 1999-04-16 | 2000-04-14 | Poly(propylene fumarate) cross linked with poly(ethylene glycol) |
Country Status (9)
Country | Link |
---|---|
US (4) | US6306821B1 (en) |
EP (3) | EP1210379B1 (en) |
JP (3) | JP2002542339A (en) |
KR (3) | KR100696407B1 (en) |
AT (3) | ATE321803T1 (en) |
AU (3) | AU760358B2 (en) |
CA (3) | CA2369758C (en) |
DE (3) | DE60034045T2 (en) |
WO (3) | WO2000062630A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106693039A (en) * | 2017-01-24 | 2017-05-24 | 南开大学 | Preparation method of medical hydrogel with good biological adhesion |
Families Citing this family (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE321803T1 (en) | 1999-04-16 | 2006-04-15 | Univ Wm Marsh Rice | FUNCTIONALIZED POLYPROPYLENE FUMARATE AND POLYPROPYLENE FUMARATE-CO-ETHYLENE GLYCOL |
US6884778B2 (en) * | 2000-04-14 | 2005-04-26 | William Marsh Rice University | Biocompatible macromers |
US20040171808A1 (en) * | 2001-05-30 | 2004-09-02 | Kazunori Kataoka | Method of bonding substance to be incorporated into polymer terminal |
WO2003002490A2 (en) * | 2001-06-28 | 2003-01-09 | Wm. Marsh Rice University | Photocrosslinking of diethyl fumarate/poly(propylene fumarate) biomaterials |
US7056338B2 (en) * | 2003-03-28 | 2006-06-06 | Conor Medsystems, Inc. | Therapeutic agent delivery device with controlled therapeutic agent release rates |
US20050064587A1 (en) * | 2001-09-07 | 2005-03-24 | Lawrence Rosenberg | Pancreatic small cells and uses thereof |
US7629388B2 (en) * | 2001-11-20 | 2009-12-08 | William Marsh Rice University | Synthesis and characterization of biodegradable cationic poly(propylene fumarate-co-ethylene glycol) copolymer hydrogels modified with agmatine for enhanced cell adhesion |
US7682803B2 (en) | 2005-10-13 | 2010-03-23 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
DE10206517A1 (en) * | 2002-02-16 | 2003-09-04 | Stoess & Co Gelatine | Depot medicinal products, carrier materials for depot medicinal products and processes for their production |
US6884432B2 (en) * | 2002-04-25 | 2005-04-26 | Mayo Foundation For Medical Education And Research | Blend, cross-linkable poly(propylene fumarate) for immobilization and controlled drug delivery |
JP2006516038A (en) * | 2002-08-09 | 2006-06-15 | オタワ ヘルス リサーチ インスティテュート | Biosynthetic substrates and uses thereof |
WO2004024035A1 (en) * | 2002-09-13 | 2004-03-25 | Ocular Sciences, Inc. | Devices and methods for improving vision |
EP1567559A4 (en) * | 2002-11-12 | 2008-04-16 | Polymer Technology Group Inc | Control of polymer surface molecular architecture via amphipathic endgroups |
US7186789B2 (en) * | 2003-06-11 | 2007-03-06 | Advanced Cardiovascular Systems, Inc. | Bioabsorbable, biobeneficial polyester polymers for use in drug eluting stent coatings |
US8518390B2 (en) | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
US20100158880A1 (en) * | 2008-12-19 | 2010-06-24 | Ethicon, Incorporated | Regeneration and repair of neural tissue following injury |
US8491883B2 (en) | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
EP1641914B1 (en) * | 2003-06-27 | 2016-07-20 | DePuy Synthes Products, Inc. | Postpartum cells derived from placental tissue, and methods of making and using the same |
US20060223177A1 (en) | 2003-06-27 | 2006-10-05 | Ethicon Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
US8790637B2 (en) * | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
US7875272B2 (en) | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
US20070043202A1 (en) * | 2003-07-01 | 2007-02-22 | Yaszemski Michael J | Self-crosslinkable poly(caprolactone fumarate) |
EP1651708B1 (en) * | 2003-07-01 | 2010-04-14 | Mayo Foundation for Medical Education and Research | Hydroxyapatite grafted fumarate based macromers for biodegradable composites |
BRPI0507169A (en) | 2004-02-02 | 2007-06-26 | Ambrx Inc | modified human growth hormone polypeptides and their uses |
US20060018949A1 (en) * | 2004-04-07 | 2006-01-26 | Bausch & Lomb Incorporated | Injectable biodegradable drug delivery system |
JP2008503217A (en) | 2004-06-18 | 2008-02-07 | アンブレツクス・インコーポレイテツド | Novel antigen-binding polypeptides and their use |
US20080260694A1 (en) | 2004-09-24 | 2008-10-23 | Angioblast Systems, Inc. | Multipotential Expanded Mesenchymal Precursor Cell Progeny (Memp) and Uses Thereof |
WO2006032075A1 (en) | 2004-09-24 | 2006-03-30 | Angioblast Systems, Inc. | Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc) |
US8039258B2 (en) * | 2004-09-28 | 2011-10-18 | Ethicon, Inc. | Tissue-engineering scaffolds containing self-assembled-peptide hydrogels |
AU2005304567B2 (en) * | 2004-11-12 | 2011-10-27 | Mayo Foundation For Medical Education And Research | Photocrosslinkable poly(caprolactone fumarate) |
US20060171930A1 (en) * | 2004-12-21 | 2006-08-03 | Agnieszka Seyda | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same |
US20060153815A1 (en) * | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
US20060166361A1 (en) * | 2004-12-21 | 2006-07-27 | Agnieszka Seyda | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
EP1836314B1 (en) | 2004-12-22 | 2012-01-25 | Ambrx, Inc. | Modified human growth hormone |
CA2594561C (en) | 2004-12-22 | 2014-12-23 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
CA2590429C (en) | 2004-12-22 | 2014-10-07 | Ambrx, Inc. | Compositions of aminoacyl-trna synthetase and uses thereof |
NZ555206A (en) | 2004-12-22 | 2010-09-30 | Ambrx Inc | Methods for expression and purification of recombinant human growth hormone |
WO2006071802A2 (en) | 2004-12-23 | 2006-07-06 | Ethicon Incorporated | Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells |
CA2604493C (en) | 2005-04-12 | 2015-12-22 | Angioblast Systems, Inc. | Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase |
JP5527968B2 (en) * | 2005-04-29 | 2014-06-25 | メイヨ フオンデーシヨン フオー メデイカル エジユケーシヨン アンド リサーチ | Hydrophilic / hydrophobic polymer networks based on poly (caprolactone fumarate), poly (ethylene glycol fumarate) and copolymers thereof |
CN103030690A (en) | 2005-06-03 | 2013-04-10 | Ambrx公司 | Improved human interferon molecules and their uses |
NZ567334A (en) | 2005-10-13 | 2012-08-31 | Anthrogenesis Corp | Production of oligodendrocytes from placenta-derived stem cells |
US20090018029A1 (en) | 2005-11-16 | 2009-01-15 | Ambrx, Inc. | Methods and Compositions Comprising Non-Natural Amino Acids |
PL1971681T3 (en) * | 2005-12-16 | 2018-01-31 | Depuy Synthes Products Inc | Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
JP5179376B2 (en) * | 2005-12-19 | 2013-04-10 | エシコン・インコーポレイテッド | In vitro growth of postpartum-extracted cells in roller bottles |
US20070160588A1 (en) * | 2005-12-28 | 2007-07-12 | Ethicon, Incorporated | Treatment Of Peripheral Vascular Disease Using Postpartum-Derived Cells |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
ES2711278T3 (en) | 2005-12-29 | 2019-04-30 | Celularity Inc | Populations of placental stem cells |
US20070182920A1 (en) * | 2006-02-08 | 2007-08-09 | Coopervision, Inc. | Corneal Onlays and Related Methods |
US7883520B2 (en) * | 2006-04-10 | 2011-02-08 | Forsight Labs, Llc | Corneal epithelial pocket formation systems, components and methods |
US8114150B2 (en) * | 2006-06-14 | 2012-02-14 | Advanced Cardiovascular Systems, Inc. | RGD peptide attached to bioabsorbable stents |
AU2007292892B9 (en) | 2006-09-08 | 2013-02-28 | Ambrx, Inc. | Hybrid suppressor tRNA for vertebrate cells |
JP5840345B2 (en) | 2006-09-08 | 2016-01-06 | アンブルックス, インコーポレイテッドAmbrx, Inc. | Modified human plasma polypeptides or modified human Fc scaffold proteins and uses thereof |
WO2008030614A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Suppressor trna transcription in vertebrate cells |
EP2420567A3 (en) | 2006-10-23 | 2015-09-30 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
NZ578819A (en) | 2007-02-12 | 2012-02-24 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
US20100172830A1 (en) * | 2007-03-29 | 2010-07-08 | Cellx Inc. | Extraembryonic Tissue cells and method of use thereof |
KR101476472B1 (en) | 2007-03-30 | 2015-01-05 | 암브룩스, 인코포레이티드 | Modified fgf-21 polypeptides and their uses |
JP2010525821A (en) | 2007-05-02 | 2010-07-29 | アンブルックス,インコーポレイテッド | Modified IFN beta polypeptides and their use |
WO2009018613A1 (en) | 2007-08-06 | 2009-02-12 | Angioblast Systems, Inc. | Methods of generating, repairing and/or maintaining connective tissue in vivo |
EP3524253A1 (en) | 2007-09-28 | 2019-08-14 | Celularity, Inc. | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
AU2008308531B2 (en) * | 2007-10-05 | 2014-04-24 | Ethicon, Incorporated | Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells |
DK2217265T3 (en) | 2007-11-20 | 2017-07-03 | Ambrx Inc | Modified insulin polypeptides and their use |
US8236538B2 (en) | 2007-12-20 | 2012-08-07 | Advanced Technologies And Regenerative Medicine, Llc | Methods for sterilizing materials containing biologically active agents |
US20090286907A1 (en) * | 2008-01-23 | 2009-11-19 | Beltz Mark W | Fumaric Acid/Diol Polyesters and Their Manufacture and Use |
CN103694337B (en) | 2008-02-08 | 2016-03-02 | Ambrx公司 | Modified leptin polypeptide and its purposes |
EP3225248B1 (en) | 2008-07-23 | 2023-06-07 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
CA2734446C (en) | 2008-08-22 | 2017-06-20 | Anthrogenesis Corporation | Methods and compositions for treatment of bone defects with placental cell populations |
KR101732054B1 (en) | 2008-09-26 | 2017-05-02 | 암브룩스, 인코포레이티드 | Non-natural amino acid replication-dependent microorganisms and vaccines |
AU2009296397B2 (en) | 2008-09-26 | 2012-11-08 | Ambrx Inc. | Modified animal erythropoietin polypeptides and their uses |
US20100087920A1 (en) * | 2008-10-07 | 2010-04-08 | Forsight Labs, Llc | Corneal Onlay Lenses and Related Methods for Improving Vision of Presbyopic Patients |
US20130302283A1 (en) | 2012-05-14 | 2013-11-14 | Advanced Technologies And Regenerative Medicine, Llc | hUTC MODULATION OF PRO-INFLAMMATORY MEDIATORS OF LUNG AND PULMONARY DISEASES AND DISORDERS |
US10179900B2 (en) * | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
AU2009327384B2 (en) | 2008-12-19 | 2014-07-10 | DePuy Synthes Products, LLC | Treatment of lung and pulmonary diseases and disorders |
ES2520393T3 (en) * | 2008-12-19 | 2014-11-11 | DePuy Synthes Products, LLC | Cells derived from umbilical cord tissue to treat neuropathic pain and spasticity |
PL2411506T3 (en) | 2009-03-25 | 2019-07-31 | Celularity, Inc. | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
CN102498204B (en) | 2009-03-26 | 2015-02-04 | 德普伊新特斯产品有限责任公司 | Human umbilical cord tissue cells as therapy for Alzheimer's disease |
EP2482828B1 (en) | 2009-10-02 | 2014-12-17 | Baxter International Inc | Hematopoietic stem cells for use in the treatment of a kidney injury |
NZ600363A (en) | 2009-12-21 | 2014-07-25 | Ambrx Inc | Modified porcine somatotropin polypeptides and their uses |
EP2805964A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
WO2011094181A1 (en) | 2010-01-26 | 2011-08-04 | Anthrogenesis Corporation | Treatment of bone-related cancers using placental stem cells |
US9144598B2 (en) | 2010-03-05 | 2015-09-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Reverse thermal gels and their use in cell therapy |
WO2011109732A2 (en) | 2010-03-05 | 2011-09-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Reverse thermal gels and uses therefor |
HUE029144T2 (en) | 2010-04-07 | 2017-02-28 | Anthrogenesis Corp | Angiogenesis using placental stem cells |
WO2011127113A1 (en) | 2010-04-08 | 2011-10-13 | Anthrogenesis Corporation | Treatment of sarcoidosis using placental stem cells |
DK2605789T3 (en) | 2010-08-17 | 2019-09-16 | Ambrx Inc | MODIFIED RELAXIN POLYPEPTIDES AND APPLICATIONS THEREOF |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
TWI480288B (en) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
WO2012092480A1 (en) | 2010-12-30 | 2012-07-05 | Anthirogenesis Corporation | Compositions comprising amnion derived adherent cells and platelet-rich plasma |
AR084754A1 (en) | 2010-12-30 | 2013-06-05 | Anthrogenesis Corp | COMPOSITIONS THAT INCLUDE MOTHER PLACENTA CELLS AND PLASMA RICH IN PLATES, AND THEIR METHODS OF USE |
AU2011352036A1 (en) | 2010-12-31 | 2013-07-18 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
KR20140012045A (en) | 2011-02-28 | 2014-01-29 | 미도리 리뉴어블즈 인코퍼레이티드 | Polymeric acid catalysts and uses thereof |
EP2706989A1 (en) * | 2011-05-09 | 2014-03-19 | Instituto Químico De Sarrià | Polymeric nanoparticles for drug delivery |
CN113559126A (en) | 2011-06-01 | 2021-10-29 | 人类起源公司 | Treatment of pain using placental stem cells |
BR112014003071A2 (en) | 2011-08-10 | 2017-02-21 | Depuy Synthes Products Llc | treatment of peripheral vascular disease using umbilical cord tissue derived cells |
AU2012358810B2 (en) | 2011-12-23 | 2018-03-15 | DePuy Synthes Products, Inc. | Detection of human umbilical cord tissue-derived cells |
EP2817014A2 (en) | 2012-02-21 | 2014-12-31 | Baxter International Inc | Pharmaceutical composition comprising cd34+ cells |
DE102012102999A1 (en) * | 2012-04-05 | 2013-10-10 | Forschungszentrum Jülich GmbH | Treating blood, blood products and/or organs under in vitro, and ex vivo condition, involves obtaining blood, blood products and/or organs from human or animal body and removing amyloid beta oligomers from products |
DK2834643T3 (en) | 2012-04-05 | 2020-02-03 | Forschungszentrum Juelich Gmbh | METHOD OF TREATING BLOOD, BLOOD PRODUCTS AND BODIES |
ES2754308T3 (en) | 2012-04-05 | 2020-04-16 | Forschungszentrum Juelich Gmbh | Polymers containing multivalent D-peptides that bind to beta-amyloid and their use |
WO2013163230A2 (en) * | 2012-04-24 | 2013-10-31 | Midori Renewables, Inc. | Bio-based polymers and methods of producing thereof |
KR102172897B1 (en) | 2012-06-08 | 2020-11-02 | 서트로 바이오파마, 인크. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
WO2014004639A1 (en) | 2012-06-26 | 2014-01-03 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
US9725698B2 (en) | 2012-07-11 | 2017-08-08 | Imstem Biotechnology, Inc. | Trophoblast-derived mesenchymal stem cells (T-MSCs) produced from human embryonic stem cells, methods and uses thereof |
US9238845B2 (en) | 2012-08-24 | 2016-01-19 | Midori Usa, Inc. | Methods of producing sugars from biomass feedstocks |
PL3584255T3 (en) | 2012-08-31 | 2022-05-16 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
EP2909314B1 (en) | 2012-10-19 | 2020-12-02 | Celularity, Inc. | Treatment of pain using amnion derived adherent cells |
CN105283075A (en) | 2012-12-14 | 2016-01-27 | 人类起源公司 | Anoikis resistant placental stem cells and uses thereof |
AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
AU2014215458A1 (en) | 2013-02-05 | 2015-08-13 | Anthrogenesis Corporation | Natural killer cells from placenta |
EP3882336A1 (en) | 2013-03-14 | 2021-09-22 | Celularity Inc. | Enhanced placental stem cells and uses thereof |
WO2014152177A1 (en) | 2013-03-15 | 2014-09-25 | Anthrogenesis Corporation | Modified t lymphocytes |
WO2015006555A2 (en) | 2013-07-10 | 2015-01-15 | Sutro Biopharma, Inc. | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
WO2015048355A1 (en) | 2013-09-26 | 2015-04-02 | Northwestern University | Poly(ethylene glycol) cross-linking of soft materials to tailor viscoelastic properties for bioprinting |
EP3055298B1 (en) | 2013-10-11 | 2020-04-29 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
SG11201609348PA (en) | 2014-05-05 | 2016-12-29 | Sealantis Ltd | Biological adhesives and sealants and methods of using the same |
UY36370A (en) | 2014-10-24 | 2016-04-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | MODIFIED FGF-21 POLIPEPTIDES AND ITS USES |
AU2015374062B2 (en) | 2014-12-31 | 2021-05-06 | Celgene Corporation | Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells |
CA2998759A1 (en) | 2015-09-15 | 2017-03-23 | Celularity Inc. | Treatment of diabetic peripheral neuropathy using placental cells |
GB201603296D0 (en) | 2016-02-25 | 2016-04-13 | Ucl Business Plc | Chemotactic,drug-containing polymersomes |
GB201604553D0 (en) * | 2016-03-17 | 2016-05-04 | Ucl Business Plc | Fumarate polymersomes |
MX2019000050A (en) | 2016-07-05 | 2019-05-02 | Janssen Biotech Inc | Treatment of retinal vascular disease using progenitor cells. |
CA3046078A1 (en) | 2016-12-05 | 2018-06-14 | Celularity Inc. | Treatment of lymphedema and related conditions using placental adherent cells |
CN110366434B (en) * | 2017-02-02 | 2022-04-05 | 阿克伦大学 | Functionalized poly (propylene fumarate) polymers prepared by ring opening polymerization using magnesium catalysts |
ES2963839T3 (en) | 2017-02-08 | 2024-04-02 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
CA3072503A1 (en) * | 2017-08-07 | 2019-02-14 | The University Of Akron | Synthesis and characterization of well defined poly(propylene fumarate) and poly(ethylene glycol) block copolymers |
WO2019067792A1 (en) | 2017-09-28 | 2019-04-04 | Celularity, Inc. | Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody |
JP7441826B2 (en) | 2018-09-11 | 2024-03-01 | アンブルックス,インコーポレイテッド | Interleukin-2 polypeptide conjugates and uses thereof |
AU2019361206A1 (en) | 2018-10-19 | 2021-06-03 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
JP2022520792A (en) | 2019-02-12 | 2022-04-01 | アンブルックス,インコーポレイテッド | Compositions, Methods, and Uses Containing Antibody-TLR Agonist Conjugates |
CA3174114A1 (en) | 2020-03-11 | 2021-09-16 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
GB2594243A (en) * | 2020-04-15 | 2021-10-27 | Arterius Ltd | A bone cement |
US11384176B2 (en) | 2020-06-26 | 2022-07-12 | Saudi Arabian Oil Company | Method of producing acryloyl monomers and acryloyl-based polymers |
JP2023538071A (en) | 2020-08-20 | 2023-09-06 | アンブルックス,インコーポレイテッド | Antibody-TLR agonist conjugates, methods and uses thereof |
CN112175191B (en) * | 2020-09-22 | 2022-07-26 | 中山大学 | Crosslinkable degradable multi-block copolymer and preparation method and application thereof |
CN112973277B (en) * | 2021-03-17 | 2022-06-14 | 济南大学 | Preparation and application of hyperbranched high-molecular polymer filter pad |
CA3213805A1 (en) | 2021-04-03 | 2022-10-06 | Feng Tian | Anti-her2 antibody-drug conjugates and uses thereof |
WO2022236187A1 (en) | 2021-05-07 | 2022-11-10 | Children's Hospital Los Angeles | Methods for making stem cell-derived enteric neural crest cells and their use in enteric neuropathy treatment |
CN114249863B (en) * | 2022-01-20 | 2023-01-24 | 西安交通大学 | Hydrogen bond enhanced photo-curing hard tissue adhesive and preparation method and use method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5286763A (en) * | 1983-03-22 | 1994-02-15 | Massachusetts Institute Of Technology | Bioerodible polymers for drug delivery in bone |
US5527864A (en) * | 1995-08-08 | 1996-06-18 | Suggs; Laura J. | Poly(propylene fumarate-co-ethylene oxide) |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3701748A (en) * | 1966-07-20 | 1972-10-31 | Rohm & Haas | Unsaturated polyester resinous compositions |
DE2061421A1 (en) * | 1970-12-14 | 1972-06-29 | Rohm & Haas | Liquid polyester compsn comprising polyester thermoplastic polymer - and monomer characterised by very low shrinkage during curing |
US4331735A (en) * | 1980-06-26 | 1982-05-25 | The General Tire & Rubber Company | One component in-mold coating |
US4722948A (en) * | 1984-03-16 | 1988-02-02 | Dynatech Corporation | Bone replacement and repair putty material from unsaturated polyester resin and vinyl pyrrolidone |
US5989579A (en) * | 1986-10-02 | 1999-11-23 | Escalon Medical Corp. | Ocular insert with anchoring protrusions |
US4843112A (en) * | 1987-03-12 | 1989-06-27 | The Beth Israel Hospital Association | Bioerodable implant composition |
JPH072836B2 (en) * | 1987-08-18 | 1995-01-18 | 帝人株式会社 | Water dispersible polyester |
US4888413A (en) * | 1988-01-11 | 1989-12-19 | Domb Abraham J | Poly(propylene glycol fumarate) compositions for biomedical applications |
US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
DK0476045T3 (en) * | 1989-06-05 | 1996-09-16 | Massachusetts Inst Technology | Biodegradable polymers for drug delivery into bones |
FI904598A0 (en) * | 1989-10-10 | 1990-09-18 | Wrigley W M Jun Co | GRADVIS AEMNESFRIGOERANDE STRUKTURER SOM FRAMSTAELLTS MED FIBERSPINNINGSTEKNIK. |
FR2661682B1 (en) * | 1990-05-04 | 1993-12-10 | Norsolor | NEW RESINOUS COMPOSITIONS BASED ON UNSATURATED POLYESTER RESINS AND NEW ANTI-SHRINKAGE ADDITIVES. |
DK0568651T3 (en) * | 1991-02-01 | 2002-08-05 | Massachusetts Inst Technology | Biodegradable polymer blends for drug delivery |
WO1993017669A1 (en) * | 1992-02-28 | 1993-09-16 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
DE69309356T2 (en) * | 1992-07-24 | 1997-11-20 | Rohm & Haas | Polyester with methacrylate groups |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
US5522895A (en) | 1993-07-23 | 1996-06-04 | Rice University | Biodegradable bone templates |
US5733951A (en) * | 1994-04-28 | 1998-03-31 | Yaszemski; Michael J. | Poly(propylene fumarate) |
EP1704878B1 (en) | 1995-12-18 | 2013-04-10 | AngioDevice International GmbH | Crosslinked polymer compositions and methods for their use |
US5998362A (en) | 1996-09-12 | 1999-12-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6071982A (en) * | 1997-04-18 | 2000-06-06 | Cambridge Scientific, Inc. | Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same |
US5854382A (en) * | 1997-08-18 | 1998-12-29 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
US5945457A (en) * | 1997-10-01 | 1999-08-31 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science | Process for preparing biologically compatible polymers and their use in medical devices |
EP1079869B1 (en) | 1998-04-10 | 2005-03-23 | Wm. MARSH RICE UNIVERSITY | Synthesis of poly(propylene fumarate) by acylation of propylene glycol in the presence of a proton scavenger |
ATE321803T1 (en) | 1999-04-16 | 2006-04-15 | Univ Wm Marsh Rice | FUNCTIONALIZED POLYPROPYLENE FUMARATE AND POLYPROPYLENE FUMARATE-CO-ETHYLENE GLYCOL |
-
2000
- 2000-04-14 AT AT00923381T patent/ATE321803T1/en not_active IP Right Cessation
- 2000-04-14 DE DE60034045T patent/DE60034045T2/en not_active Expired - Lifetime
- 2000-04-14 KR KR1020017013176A patent/KR100696407B1/en not_active IP Right Cessation
- 2000-04-14 AU AU43518/00A patent/AU760358B2/en not_active Ceased
- 2000-04-14 AT AT00928174T patent/ATE448274T1/en not_active IP Right Cessation
- 2000-04-14 AU AU43496/00A patent/AU775913B2/en not_active Ceased
- 2000-04-14 WO PCT/US2000/010139 patent/WO2000062630A1/en active IP Right Grant
- 2000-04-14 EP EP00923355A patent/EP1210379B1/en not_active Expired - Lifetime
- 2000-04-14 DE DE60043304T patent/DE60043304D1/en not_active Expired - Lifetime
- 2000-04-14 DE DE60026983T patent/DE60026983T2/en not_active Expired - Fee Related
- 2000-04-14 WO PCT/US2000/010051 patent/WO2000063268A1/en active IP Right Grant
- 2000-04-14 US US09/549,483 patent/US6306821B1/en not_active Expired - Lifetime
- 2000-04-14 EP EP00923381A patent/EP1171006B1/en not_active Expired - Lifetime
- 2000-04-14 US US09/549,485 patent/US6423790B1/en not_active Expired - Fee Related
- 2000-04-14 JP JP2000611774A patent/JP2002542339A/en active Pending
- 2000-04-14 US US09/550,372 patent/US6384105B1/en not_active Expired - Fee Related
- 2000-04-14 JP JP2000612353A patent/JP4644374B2/en not_active Expired - Fee Related
- 2000-04-14 EP EP00928174A patent/EP1194463B1/en not_active Expired - Lifetime
- 2000-04-14 CA CA002369758A patent/CA2369758C/en not_active Expired - Fee Related
- 2000-04-14 WO PCT/US2000/010049 patent/WO2000063263A1/en active IP Right Grant
- 2000-04-14 JP JP2000612348A patent/JP2002542349A/en active Pending
- 2000-04-14 CA CA002370357A patent/CA2370357C/en not_active Expired - Fee Related
- 2000-04-14 CA CA002370330A patent/CA2370330C/en not_active Expired - Fee Related
- 2000-04-14 AT AT00923355T patent/ATE357468T1/en not_active IP Right Cessation
- 2000-04-14 KR KR1020017013177A patent/KR100696408B1/en not_active IP Right Cessation
- 2000-04-14 AU AU46447/00A patent/AU770579B2/en not_active Ceased
- 2000-04-14 KR KR1020017013175A patent/KR100619611B1/en not_active IP Right Cessation
-
2002
- 2002-04-22 US US10/127,117 patent/US6759485B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5286763A (en) * | 1983-03-22 | 1994-02-15 | Massachusetts Institute Of Technology | Bioerodible polymers for drug delivery in bone |
US5527864A (en) * | 1995-08-08 | 1996-06-18 | Suggs; Laura J. | Poly(propylene fumarate-co-ethylene oxide) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106693039A (en) * | 2017-01-24 | 2017-05-24 | 南开大学 | Preparation method of medical hydrogel with good biological adhesion |
CN106693039B (en) * | 2017-01-24 | 2019-10-01 | 南开大学 | A kind of preparation method of the medical aquogel with good biological adhesiveness |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1210379B1 (en) | Biodegradable poly(propylene fumarate) networks cross linked with poly(propylene fumarate)-diacrylate macromers | |
He et al. | Synthesis of biodegradable poly (propylene fumarate) networks with poly (propylene fumarate)–diacrylate macromers as crosslinking agents and characterization of their degradation products | |
US5644002A (en) | Absorbable polyalkylene diglycolates | |
US5688900A (en) | Absorbable polyalkylene diglycolates | |
EP1642921B1 (en) | Triblock copolymer, method for producing the same and biocompatible material | |
Peter et al. | Poly (propylene fumarate) | |
Akdemir et al. | Preparation of biocompatible, UV-cured fumarated poly (ether-ester)-based tissue-engineering hydrogels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2370330 Country of ref document: CA Ref country code: CA Ref document number: 2370330 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017013176 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 612348 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000923355 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017013176 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000923355 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020017013176 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000923355 Country of ref document: EP |